5-bromo-4-chloro-3-indolyl beta-galactoside has been researched along with Hepatic Failure in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nishimaki, T; Nozato, E; Shiraishi, M | 1 |
1 other study(ies) available for 5-bromo-4-chloro-3-indolyl beta-galactoside and Hepatic Failure
| Article | Year |
|---|---|
Up-regulation of hepatocyte growth factor caused by an over-expression of transforming growth factor beta, in the rat model of fulminant hepatic failure.
Topics: Adenoviridae; Alanine Transaminase; Animals; Apoptosis; Aspartate Aminotransferases; Body Weight; Cytokines; Disease Models, Animal; Galactosides; Gene Expression; Gene Transfer Techniques; Hepatocyte Growth Factor; Hepatocytes; In Situ Nick-End Labeling; In Vitro Techniques; Indoles; Liver Failure; Liver Regeneration; Male; Necrosis; Organ Size; Proliferating Cell Nuclear Antigen; Rats; Rats, Wistar; Staining and Labeling; Transforming Growth Factor beta; Transforming Growth Factor beta1; Up-Regulation | 2003 |